Particularly with newer biologic agents including TNF blockers, further studies are needed to better determine if there is an increased cancer risk with the therapies themselves, with the higher doses, and longer treatments, or whether any increased cancer risk is due to underlying severe disease. The gene discussed is TNF; the disease is cancer.